An emerging biomarker for atherosclerosis is present in some patients with hepatitis C virus (HCV) infection, a recent study found. This study investigated a novel independent biomarker for CVD, autoantibodies to apolipoprotein A-1 (anti-apoA-1 IgG) and lipids in patients with chronic HCV before, during, and after direct-acting antiviral (DAA) therapy. 89 blinded serum samples from 27 patients with advanced chronic HCV were assayed for lipids and anti-apoA-1 IgG. Researchers found:
- Pretreatment HCV viral load correlated with high-density lipoprotein cholesterol (HDL-C) and negatively with apolipoprotein (apo)B and markers of CVD risk, the apoB/apoA-1 ratio, and triglyceride level (TG)/HDL-C ratio.
- 14 (52%) of patients had detectable anti-apoA-1 IgG autoantibodies pretreatment; only 2 became undetectable with virological cure.
- Autoantibody-positive sera had lower apoA-1, HDL-C, and total cholesterol levels.
Bridge SH, Pagano S, Jones M, et al. Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: A role in atherosclerosis? [Published online ahead of print February 8, 2018]. Hepatol Int. doi:10.1007/s12072-018-9842-5.
This Week's Must Reads
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al